Anne Marinier

11PUBLICATIONS

104CO-AUTHORS

Molecular targetsGene expression (incl. microarray and other genome-wide approaches)Biologically active moleculesHaematological tumoursMedical molecular engineering of nucleic acids and proteins

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|May 20, 2026

Targeting the H/KRAS α4-β6-α5 Allosteric Lobe with Macrocyclic Peptides.

|Feb 09, 2026

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

Jasmin Coulombe-Huntington, Thierry Bertomeu, Caroline Huard

|May 29, 2025

BRAF oncogenic mutants evade autoinhibition through a common mechanism.

Hugo Lavoie, Ting Jin, Driss Lajoie

|Apr 28, 2025

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

Céline Moison, Rodrigo Mendoza-Sanchez, Deanne Gracias

|Mar 22, 2024

<i>SF3B1</i> mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia.

Céline Moison, Deanne Gracias, Julie Schmitt

|Jul 07, 2022

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.

Céline Moison, Jean-François Spinella, Jalila Chagraoui

Pageof 2

Frequent Collaborators

Pierre Thibault

Doris A Schuetz

Hugo Lavoie

Guy Sauvageau

Thierry Bertomeu

Eric Bonneil

Céline Moison

Frank Sicheri

Daniel St-Cyr

Almer M van der Sloot

Frequent Collaborators

Pierre Thibault

Doris A Schuetz

Hugo Lavoie

Guy Sauvageau